Find Academic Supervisors

Laura SoltView profile

Associate Professor

• Autoimmune Disease
• Cancer Immunotherapy
• Immunometabolism
• +5 more

Laura Solt, Ph.D. is an Associate Professor in the Department of Immunology and Microbiology at the Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology in Jupiter, Florida. She also serves as Associate Dean of the Skaggs Graduate School of Chemical and Biological Sciences. Dr. Solt began her independent research career at Scripps Florida in 2013 and has established herself as a leading researcher in nuclear receptor biology within the immune system. Her research focuses on understanding the biologically relevant roles of nuclear receptors, particularly RORα and REV-ERBs, in the immune system with emphasis on TH17 cell development and autoimmune disease. Her lab employs a multidisciplinary approach combining molecular biology, genetic techniques, and chemical biology coupled with mouse models of autoimmunity and chronic inflammation. Dr. Solt's laboratory has made significant contributions to understanding how nuclear receptors regulate immune cell function, particularly in TH17-mediated inflammation. Her work has demonstrated roles for RORα and REV-ERBs in TH17 cell development and has developed synthetic ligands to these receptors for potential therapeutic applications in autoimmune diseases. Her extensive publication record shows a clear trajectory of research focused on nuclear receptor signaling in immunity, with recent work expanding into applications for cancer immunotherapy, neuroimmunology, and metabolic aspects of immune cell function. Her articles demonstrate expertise in both basic nuclear receptor mechanisms and translational applications. Ruth L. Kirschstein National Research Service Awards (2010-2013) Dr. Solt actively mentors graduate students including Adrianna Wilson (recipient of NIDDK F31 and Scheller Graduate Student Fellowship) and Sarah Mosure (recipient of NIH NRSA F31 award and Wendy Havran award). Her laboratory receives substantial funding from multiple NIH institutes (NIDDK, NCI, NIAID, NIGMS) as well as the Crohn's & Colitis Foundation. Current research directions include investigating the roles of NR2F6 in TH17 cells, exploring RORα function in CD8 T cells, and developing novel nuclear receptor modulators for therapeutic applications.

Xenophon PapademetrisView profile

Professor

• Medical Image Analysis
• Machine Learning
• Biomedical Software Development
• +7 more

Xenophon Papademetris is a Professor of Biomedical Informatics & Data Science and Radiology & Biomedical Imaging at Yale School of Medicine. He serves as Associate Director of Biomedical Imaging Data Sciences at Yale Biomedical Imaging Institute and directs the Medical Software and Medical Artificial Intelligence Certificate Program. PhD in Electrical and Information Sciences from Yale University (2000) BA from Cambridge University (1994) Postdoctoral Fellowship at Yale University (2002) His research focuses on medical image analysis, machine learning, and biomedical software development. He has developed tools like BioImage Suite Web and contributed to standards committees at the Association for the Advancement of Medical Instrumentation (AAMI). His work spans modalities including MRI, CT, PET, and optical imaging. Recent publications emphasize neuroimaging analysis, explainable AI in healthcare, and multimodal data integration across species. He leads NIH-funded research under the BRAIN Initiative (R24 MH114805) and has authored a textbook on Medical Software published by Cambridge University Press. IEEE Senior Member Yale Brown-Coxe Postdoctoral Fellowship Harding Bliss Prize for Excellence in Engineering He directs the BioImage Suite Project, creating web-based image analysis tools using JavaScript and WebAssembly. His teaching includes both academic courses and a Coursera program on Medical Software with over 14,000 enrollments.

David AckerleyView profile

Professor

• Enzymes
• Synthetic biology
• Microbiology
• +4 more

Professor David Ackerley (Victoria University of Wellington) is a leading microbiologist and enzyme engineer specializing in directed evolution of bacterial enzymes for biotechnological applications. As Biotechnology Programme Director since 2006, he lectures in foundational courses like BTEC101 and BTEC201. Academic rank: Professor of Biotechnology Institutional affiliation: Victoria University of Wellington Research focus areas: Microbial Biotechnology, Drug Discovery, Synthetic Biology His research employs Darwinian evolutionary principles to engineer enzymes with enhanced activities, particularly targeting non-ribosomal peptide synthetases and nitroreductases for antibiotic development and cancer therapy. Recent work explores metagenomic domain substitution in pyoverdine biosynthesis and Purpuramine R from marine sponges. Key publications demonstrate innovations in metagenomic library construction , CRISPR screening for regeneration genes, and structural characterization of engineered enzymes. His team has developed NTR 2.0 , a high-efficacy nitroreductase for targeted cell ablation. Current research projects include: Clean solutions from dirty genes: Plastic-degrading enzyme discovery Engineering enzymes for CAR T-cell-chemotherapy synergy Repurposing niclosamide against Gram-negative superbugs Grants from the Health Research Council of New Zealand, Royal Society of New Zealand, and Cancer Society of NZ support his work. Collaborations span biomedical research, synthetic biology, and environmental applications.

• Molecular Structure and Self-Assembly
• Protein Folding and Misfolding
• Amyloid Fibril Formation
• +7 more

Ehud Gazit is a distinguished Professor in the Department of Molecular Microbiology and Biotechnology at Tel Aviv University's Faculty of Life Sciences. He holds the Chair for Nano-Biology and serves as Vice President for Research and Development at Tel Aviv University. Professor Gazit has held numerous prestigious visiting appointments including at Umeå University, Fudan University, and Cambridge University. His academic journey began with a B.Sc. (summa cum laude) from Tel Aviv University's Special University Program for Outstanding Students in 1991, followed by a Ph.D. (with distinction) from the Weizmann Institute of Science in 1997, and postdoctoral training at MIT from 1997-2000. Professor Gazit's research focuses on molecular structure and self-assembly at the nano-scale, particularly examining protein folding, unfolding, and misfolding phenomena. His laboratory investigates the mechanisms and significance of protein unfolding and misfolding, with experimental systems including bacterial toxin-antidote systems, type II diabetes-related amyloidogenic proteins, and the VHL tumor suppressor protein. His work bridges fundamental biochemistry with nanotechnology applications, exploring how molecular self-assembly can be harnessed for technological innovation. His recent publications demonstrate a strong trajectory in peptide-based nanomaterials, with particular emphasis on amyloid formation mechanisms, peptide self-assembly for functional materials, and therapeutic applications targeting neurodegenerative diseases. His work spans multiple disciplines including biochemistry, nanotechnology, materials science, and biomedical engineering, showing increasing integration of fundamental research with practical applications. Professor Gazit has received numerous prestigious awards including: 2020 Landau Prize in Sciences and Arts in the Field of Healthy Aging 2019 Rappaport Prize for Excellence in Biomedical Research 2018 Foreign Fellow of the National Academy of Sciences, India 2016 ERC Advanced Grant from the European Research Council 2015 Elected Member of the European Molecular Biology Organization (EMBO) Professor Gazit has been actively involved in mentoring students and researchers, as evidenced by his extensive publication record with numerous collaborators. He has secured significant research funding including an ERC Advanced Grant. His professional activities include editorial board memberships for journals including Journal of Peptide Science, Nanoscience & Nanotechnology - Asia, and Amyloid. He previously served as Chief Scientist of the Ministry of Science and Technology (2012-2014). His laboratory has developed innovative approaches to studying molecular self-assembly, with particular expertise in peptide nanostructures. The research team has made significant contributions to understanding amyloid formation mechanisms while simultaneously developing novel biomaterials with applications ranging from electronics to medicine. They have established strong collaborations with research groups worldwide, creating a dynamic interdisciplinary research environment focused on the intersection of biology and nanotechnology.

Zhi-Ping FengView profile

Researcher

• Bioinformatics
• Genomics
• Proteomics
• +3 more

Dr. Zhi-Ping Feng is a Bioinformatician at the John Curtin School of Medical Research (JCSMR), Australian National University (ANU). Her research focuses on integrating omics data with protein structure-function relationships to study interactions between macromolecules. She has expertise in analyzing genomic and transcriptomic data (e.g., RNA-Seq, ChIP-Seq) and protein structure determination via nuclear magnetic resonance (NMR) spectroscopy. Previously, she held a Senior Research Fellow position at the Walter and Eliza Hall Institute (WEHI) from 2009, working on quality control in omics research and genomic data analysis. Her postdoctoral work at WEHI (2002–2005) involved structural biology of malaria-related proteins, supported by an Australian Postdoctoral Fellowship. She holds a PhD in protein bioinformatics from China and a physics background from Peking University. Education: PhD in Protein Bioinformatics (China) Bachelor’s in Physics, Peking University Research Interests: Her work bridges computational biology and structural biology, with emphasis on: Intrinsically unstructured proteins (IUPs) and their applications in malaria proteomics Omics data integration for disease modeling (e.g., cancer, diabetes, neurodegeneration) Protein-protein interaction networks and structural bioinformatics Publications: Recent work spans cancer immunotherapy, miRNA regulation in retinal degeneration, and T cell biology, with contributions to understanding Wnt signaling in joint replacement complications and genetic fusions in pediatric brain tumors. Awards: Australian Postdoctoral Fellowship (2005) Grants/Teams: Currently affiliated with ANU Bioinformatics Consultancy, supporting translational medical research in immunology, cancer, and genomics. Labs/Teams: Collaborates with the JCSMR’s multidisciplinary teams focusing on biomedical informatics and translational research.

Dean R. TolanView profile

Professor

• Biochemistry
• Enzymology
• Molecular Genetics
• +3 more

Dean R. Tolan is a Professor of Biology and Director of Undergraduate Studies at Boston University. His research focuses on the biochemical and genetic mechanisms underlying sugar metabolism, particularly the glycolytic enzyme aldolase and its role in hereditary fructose intolerance (HFI). He leads a laboratory investigating aldolase structure-function relationships, moonlighting functions in cell motility, and the pathophysiology of HFI using mouse models. His work integrates structural biology (X-ray crystallography, electron microscopy), genetic analysis, and metabolomics. Key research themes include: (1) Structural basis of aldolase isoforms' catalytic differences; (2) Genetic defects causing HFI and their clinical manifestations; (3) Evolutionary adaptation of aldolase moonlighting roles. He teaches core biochemistry courses (BI108, BB421/422, MB722). Notable achievements include pioneering studies on aldolase B knockout mice mimicking human HFI, and discoveries linking fructose metabolism to metabolic syndrome, cancer, and neurodegenerative diseases. His lab collaborates internationally on projects funded by NIH and other agencies.

Lon S. SchneiderView profile

Professor

• Alzheimer's Disease Research
• Dementia
• Psychiatry
• +5 more

Lon S. Schneider, MD, MS is Professor of Psychiatry & the Behavioral Sciences at the Keck School of Medicine of the University of Southern California, where he holds the Della Martin Chair in Psychiatry and Neuroscience. He directs the USC California Alzheimer's Disease Center (funded by the California Department of Health Services), the Geriatric Studies Center, and co-directs the clinical core of the USC NIA Alzheimer's Disease Research Center. Dr. Schneider's research focuses on treatment development with novel metabolic and neuroregenerative compounds, outcomes assessment, and approaches to modeling, clinical trials methods and simulations, and in silico screening of medications for slowing Alzheimer's disease. His work spans Alzheimer's disease therapeutics, clinical trial methodology, neuropsychopharmacology, dementia prevention, and neurodegenerative biomarkers. His recent publications demonstrate expertise in amyloid and tau biomarkers, clinical trial design, agitation management in dementia, and cross-cultural studies of cognitive decline. Dr. Schneider serves as an associate editor or editorial board member for several publications and is a member of The Lancet Commission on dementia prevention, intervention, and care. His research has significantly influenced clinical practice and trial design in Alzheimer's disease. Woodward/White, Inc.: The Best Doctors in America, 1992-2009 Fellow of the American College of Neuropsychopharmacology Distinguished Life Fellow of the American Psychiatric Association Dr. Schneider has mentored numerous researchers and clinicians in the field of geriatric psychiatry and Alzheimer's disease research. His work on the CitAD trial examining citalopram for agitation in Alzheimer's dementia represents one of the largest studies of its kind. He has contributed significantly to understanding the relationship between neuropsychiatric symptoms and functional decline in dementia, as well as developing novel measures for Alzheimer's disease prevention trials. His laboratory and clinical research programs focus on identifying biomarkers of disease progression, developing novel therapeutic approaches for Alzheimer's disease, and improving clinical trial methodology for neurodegenerative disorders. Dr. Schneider collaborates extensively with researchers across USC and internationally on multi-center clinical trials and observational studies of dementia.

• Neuroscience
• Neurophysiology
• Computational Biology
• +3 more

Dario Ringach is a Professor in the Department of Neurobiology at the University of California, Los Angeles (UCLA) School of Medicine . His research focuses on neural coding , visual cortex organization , and population dynamics in sensory processing . Key projects include studies on energy-efficient coding , Bayesian network estimation , and cortical adaptation mechanisms . NIH R01NS116471 (2020-2023): Population codes and sensory discrimination NIH R01EB022915 (2016-2021): Bayesian connectivity estimation NIH R01EY018322 (2007-2019): Theoretical visual cortex studies NIH R01EY012816 (2000-2011): Quantitative cortical processing His work spans Neuroscience , Computational Biology , and Neurophysiology , with recent emphasis on adaptation geometry , population coding , and neural normalization . Publications analyze mouse models and primate visual systems , covering topics like receptive field development , thalamocortical connectivity , and inhibitory circuits . Contributions include theoretical frameworks for energy efficiency and power laws in cortical processing. Key collaborations include researchers such as Joshua Trachtenberg (UCLA), Mario Dipoppa (UCLA), and Mark Frye (UCLA). He advocates for responsible animal research in neuroscience and has contributed to debates on scientific ethics and methodological transparency .

• Ophthalmology
• Retinal Research
• Stem Cell Therapy
• +4 more

Mark Fields, MPH, PhD is an Associate Professor in the Department of Ophthalmology & Visual Science at Yale School of Medicine. He also has affiliations with the Yale Stem Cell Center, reflecting his research focus at the intersection of ophthalmology and regenerative medicine. Dr. Fields' research interests center on retinal biology, with specific expertise in the outer blood-retinal barrier, Bruch's membrane, and retinal pigment epithelium. His work investigates the structural and functional relationships between these critical ocular components and explores potential applications for stem cell therapy in treating eye diseases. His recent publications demonstrate a consistent focus on understanding the complex interactions within the retina and developing innovative approaches for retinal repair and regeneration. Dr. Fields' research combines fundamental anatomical studies with translational applications, particularly in the context of age-related changes in ocular structures. Dr. Fields maintains active research collaborations with several prominent Yale researchers including Jie Gong, Lawrence Rizzolo, and Ron Adelman, indicating strong interdisciplinary connections within Yale's ophthalmology and visual science community.

Pablo Altschwager KreftView profile

Assistant Professor

• Ophthalmology
• Medical Retina
• Pediatric Ophthalmology
• +3 more

Pablo Altschwager Kreft is an Ophthalmologist and Instructor of Ophthalmology at Harvard Medical School, affiliated with Boston Children's Hospital. His work focuses on pediatric medical retina and genetic eye disorders, integrating clinical practice with research in retinal degeneration and telemedicine applications. Research Interests: His research spans retinal electrophysiology, macular structure-function relationships, and the impact of preterm birth on retinal development. He has contributed to understanding juvenile macular degenerations and syndrome-associated ocular pathologies, with a strong emphasis on diagnostic advancements in medical retina. Publications: Recent work includes studies on Multifocal ERG in preterm infants Telemedicine during the pandemic CRB2-related syndromic retinal degeneration

• Glaucoma Research
• Visual Field Testing
• Age-Related Macular Degeneration
• +7 more

Professor David P. Crabb is a leading researcher in the Department of Optometry and Visual Science within the School of Health Sciences at City, University of London. With over 180 publications spanning from 2010 to 2025, his work has significantly contributed to the fields of glaucoma research, age-related macular degeneration, and visual field testing methodologies. He is particularly known for his involvement in the MACUSTAR study, a major international research initiative focused on developing clinical endpoints for intermediate age-related macular degeneration. Crabb's research interests span a wide range of ophthalmic topics with particular emphasis on visual field progression in glaucoma, structure-function relationships in retinal diseases, and patient-centered outcomes in eye care. His work has consistently bridged the gap between clinical practice and research methodology, developing novel approaches to visual field testing and analysis. He has made substantial contributions to understanding eye movements in patients with visual field loss and their implications for daily functioning. His recent publications (2024-2025) demonstrate continued leadership in the field, with significant contributions to MACUSTAR study reports, glaucoma progression analysis, and patient-centered research in geographic atrophy. These works showcase his dual focus on technical innovation in visual assessment and the practical implications for patient care and quality of life. Professor Crabb has collaborated extensively with international research groups across Europe and has contributed to major multicenter studies including the United Kingdom Glaucoma Treatment Study (UKGTS) and the LiGHT trial. His work frequently appears in top ophthalmology journals including Ophthalmology, Investigative Ophthalmology & Visual Science, and American Journal of Ophthalmology. His research methodology often combines traditional clinical approaches with advanced data analysis techniques, including machine learning applications for predicting visual field progression and optimizing testing protocols. This interdisciplinary approach has positioned him as a key contributor to evidence-based practice in ophthalmology.

• Organic Chemistry
• Phytochemistry
• Natural Products Research
• +3 more

Dr. Eduard Mas Claret is a Visiting Research Fellow in the School of Chemistry and Chemical Engineering at the University of Surrey. His research focuses on the isolation and biological evaluation of natural products, particularly from plant species, to identify compounds with potential medicinal applications in cancer therapy, anti-angiogenesis, and cardiovascular health. He collaborates extensively with international researchers and contributes to drug discovery efforts through phytochemical studies and pharmacological screening. Dr. Mas Claret's research interests span organic chemistry, phytochemistry, and natural products research. He specializes in the isolation of bioactive compounds from plants, such as diterpenoids, alkaloids, and homoisoflavonoids, and evaluates their anti-cancer, anti-angiogenic, and vasorelaxant properties. His work often involves structural determination using NMR and MS, and assessing biological activity against cancer cell lines or in cardiovascular models. His publications highlight contributions to understanding plant-derived compounds' mechanisms, including their effects on melanin production, vascular function, and DNA repair pathways. He has collaborated with institutions such as the University of KwaZulu-Natal and the University of Malawi on projects involving African flora. No information provided on scientific awards, advising students, or grants. Engaged in collaborative projects within the University of Surrey's School of Chemistry and Chemical Engineering, focusing on natural products and drug discovery.

Virginie HamelView profile

Lecturer

• Molecular Biology
• Cellular Biology
• Structural Biology
• +5 more

Virginie Hamel is a Lecturer and Researcher at the University of Geneva in the Department of Molecular and Cellular Biology. She co-leads a structural cell biology lab with Dr. Paul Guichard, focusing on centriole and connecting cilium assembly in photoreceptor cells and immune synapse architecture . Core Research Areas: Molecular mechanisms of ciliary structure-function relationships, retinal degeneration in ciliopathies, and expansion microscopy (U-ExM) development for ultrastructural analysis. Collaborations: Key partnerships with Dr. Corinne Kostic/Prof. Yvan Arsenijevic (Jules-Gonin Hospital, UNIL) and Prof. Ronald Roepman for retinal disease studies. Recent Work: Publications on FAM161A , LCA5 , and AGBL5 gene mutations linked to retinal ciliary defects, using U-ExM and cryo-tomography to visualize disease mechanisms. Lab Affiliation: Part of the GenExM team, working with technicians, postdocs, and PhD students like Lorène Bournonville on photoreceptor ultrastructure.

Jason SelloView profile

Professor

• Bacterial Proteins
• Mycobacterium tuberculosis
• Proteasome Inhibitors
• +3 more

Jason Sello is a Professor in the Department of Pharmaceutical Chemistry at the University of California San Francisco (UCSF), holding roles as Vice Dean of Academic Affairs and Executive Committee Member. His research focuses on bacterial proteins, antibiotic resistance mechanisms, and natural product synthesis, particularly targeting pathogens like Mycobacterium tuberculosis and Candida species. He leads efforts in developing proteasome inhibitors and novel antibacterial agents through multidisciplinary approaches. Key affiliations include the Quantitative Biosciences Institute (QBI) and the Chan Zuckerberg Biohub. His work spans chemical synthesis, microbial genetics, and drug discovery, with contributions to understanding efflux pump mechanisms and retrograde trafficking inhibitors. Notable achievements include the synthesis of cyclomarin natural products and the development of small molecules restoring antifungal efficacy against drug-resistant Candida strains. His research integrates organic chemistry, microbiology, and pharmacology, addressing challenges in antibiotic resistance and drug delivery. Recent publications highlight in vivo approaches for neuroactive molecules and the mechanistic study of ClpP proteases in tuberculosis. Sello also contributes to institutional leadership, including equity initiatives in pharmacy education and diversity outreach programs.

Carl J. BassiView profile

Teaching Professor

• Visual System Assessment
• Color Vision Research
• Photophobia
• +5 more

Carl J. Bassi is a Teaching Professor and Director of Research at the College of Optometry , University of Missouri–St. Louis. His work focuses on advancing visual system evaluation in patient populations through interdisciplinary methodologies. Contact: Email: bassi@umsl.edu | Phone: (314) 516-6029 | Office: 419 Marillac Hall Research Interests: Dr. Bassi’s laboratory develops novel devices for assessing color vision, visual suppression, and photophobia. He investigates the impact of macular pigment zeaxanthin on visual function, evaluates color vision in applied settings, and employs electrophysiological (ERGs, VEPs) and psychophysical techniques (contrast sensitivity, stereopsis) to study structure-function relationships in dementia, glaucoma, macular degeneration, and retinal abnormalities. Scientific Awards: Curator's Distinguished Teaching Professor Weldon Springs award Grants & Collaborations: Funded by Northrup-Grumman Technologies, Zeavision, Missouri Alzheimer's Association, University of Missouri Research Board, and industry partnerships.